Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab

Ramy Abdelmaseih; Randa Abdelmasih; Mustajab Hasan; Alan Hamza

doi:10.7759/CUREUS.15467

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab

Ramy Abdelmaseih
, Randa Abdelmasih
, Mustajab Hasan
, Alan Hamza

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cureus
DOIs	https://doi.org/10.7759/CUREUS.15467
State	Published - Jun 5 2021

Disciplines

Medicine and Health Sciences
Cardiology
Internal Medicine

Access to Document

10.7759/CUREUS.15467License: Unspecified

Cite this

@article{a54ec429dfe14e3c9c8f18a1e0e60413,

title = "Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab",

author = "Ramy Abdelmaseih and Randa Abdelmasih and Mustajab Hasan and Alan Hamza",

note = "Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible side effect, atrial fibrillation (AF), encountered with evolocumab to increase the awareness among physicians of such a possibility.",

year = "2021",

month = jun,

day = "5",

doi = "10.7759/CUREUS.15467",

language = "American English",

journal = "Cureus",

publisher = "Springer",

}

TY - JOUR

T1 - Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab

AU - Abdelmaseih, Ramy

AU - Abdelmasih, Randa

AU - Hasan, Mustajab

AU - Hamza, Alan

N1 - Evolocumab is a recently FDA-approved proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) that reduces the risk of myocardial infarction, stroke, and coronary revascularization in individuals with established atherosclerotic cardiovascular disease. We report an extremely rare possible side effect, atrial fibrillation (AF), encountered with evolocumab to increase the awareness among physicians of such a possibility.

PY - 2021/6/5

Y1 - 2021/6/5

UR - https://www.cureus.com/articles/61261-atrial-fibrillation-as-a-possible-adverse-reaction-to-evolocumab

U2 - 10.7759/CUREUS.15467

DO - 10.7759/CUREUS.15467

M3 - Article

JO - Cureus

JF - Cureus

ER -

Atrial Fibrillation as a Possible Adverse Reaction to Evolocumab

Disciplines

Access to Document

Other files and links

Cite this